FIELD: pharmacology.
SUBSTANCE: invention relates to application of a compound with the chemical formula Tyr-dAla-Phe-Gly-Phe-Leu-NH2 as a means for increase of heart resistance to reperfusion damage, for example, to reduce myocardial damage in ischemia/reperfusion in patients with acute myocardial infarction, during cardiosurgical interventions using artificial circulation and during heart transplantation.
EFFECT: increased means efficiency.
3 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF CARDIOPROTECTION OF ISCHEMIC AND REPERFUSION INJURIES IN ACUTE MYOCARDIAL INFARCTION | 2019 |
|
RU2712448C1 |
| AGENT IMPROVING CARDIAC RESISTANCE TO ISCHEMIC AND FOLLOWING REPERFUSION INJURIES | 2012 |
|
RU2488404C1 |
| IMPROVING THE RECOVERY FUNCTION OF THE CARDIOVASCULAR SYSTEM IN ISCHEMIA TETRADECAPEPTIDES | 2017 |
|
RU2648846C1 |
| AGENT SIMULATING CARDIAC POSTCONDITIONING PHENOMENON | 2012 |
|
RU2502508C1 |
| CRYSTALLOID CARDIOPLEGIC SOLUTIONS, CONTAINING DODECAPEPTIDES (VERSIONS) | 2013 |
|
RU2549470C1 |
| METHOD FOR SIMULATION OF INCREASED STABILITY OF RAT MYOCARDIUM TO ISCHEMIC-REPERFUSION DAMAGE | 2016 |
|
RU2623727C1 |
| USE OF PHOSPHOLIPID EMULSION CONTAINING EFFECTIVE AMOUNT OF DIHYDROQUERCETIN FOR TREATING ISCHEMIA-REPERFUSION SYNDROME IN PATIENTS WITH ISCHEMIC ORGAN AND EXTREMITY INJURIES | 2021 |
|
RU2766681C1 |
| DODECAPEPTIDES HAVING CARDIOPROTECTIVE PROPERTIES | 2010 |
|
RU2457216C1 |
| CARDIOPROTECTIVE AGENT | 2020 |
|
RU2743764C1 |
| AGENT POSSESSING CARDIOPROTECTIVE ACTIVITY | 2019 |
|
RU2699039C1 |
